血液科

订阅

MedSci主页 / 所有栏目 / 血液科

J Clin Invest：PD-L1在GVL与GVHD中的研究进展

2017-04-18 MedSci MedSci原创

PD-L1GVLGVHD
关注

目前，由于对供体衍生的同种异体反应性T细胞介导的移植物抗白血病/淋巴瘤（GVL）作用的良好认识，异基因造血细胞移植（HCT）代表了可用于治疗各种血液恶性肿瘤的一种方法。然而，移植物抗宿主病（GVHD）是由相同的T细胞介导，并且其仍然是导致大量发病率和死亡率的重大临床问题。近期，在杂志JCI发表的文章中，研究者Ni及其同事使用了几种GVHD鼠模型来评估CD4 + T细胞的消耗对GVL与GVHD的影响


目前，由于对供体衍生的同种异体反应性T细胞介导的移植物抗白血病/淋巴瘤（GVL）作用的良好认识，异基因造血细胞移植（HCT）代表了可用于治疗各种血液恶性肿瘤的一种方法。

然而，移植物抗宿主病（GVHD）是由相同的T细胞介导，并且其仍然是导致大量发病率和死亡率的重大临床问题。

近期，在杂志JCI发表的文章中，研究者Ni及其同事使用了几种GVHD鼠模型来评估CD4 + T细胞的消耗对GVL与GVHD的影响，并显示了CD4 + T细胞的消耗导致通过受体组织和供体CD8 + T细胞介导的PD-L1的上调。 

PD-L1与PD-1在GVHD靶向组织中的相互作用导致CD8 + T细胞的衰竭和凋亡，从而阻止GVHD的发生，而PD-L1与淋巴组织中CD80的相互作用促进CD8 + T细胞的存活和扩增，从而增强了GVL反应。

这些研究结果可能为开发有效的临床策略以增强GVL，同时最小化同种异体HCT后发生GVHD奠定基础。

原始出处：
Brennan TV, Yang Y. PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest. 2017 Apr 17. pii: 94196. doi: 10.1172/JCI94196.
 
本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050649, encodeId=19cc205064976, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 10 18:13:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254914, encodeId=b8361254914db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380779, encodeId=c9b31380e7943, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188695, encodeId=515b18869547, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Wed Apr 19 07:19:47 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-06-10 xiangyuzhou971

    #EST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2050649, encodeId=19cc205064976, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 10 18:13:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254914, encodeId=b8361254914db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380779, encodeId=c9b31380e7943, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188695, encodeId=515b18869547, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Wed Apr 19 07:19:47 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-04-20 smartjoy

    #PD-L1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2050649, encodeId=19cc205064976, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 10 18:13:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254914, encodeId=b8361254914db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380779, encodeId=c9b31380e7943, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188695, encodeId=515b18869547, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Wed Apr 19 07:19:47 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-04-20 mashirong

    #研究进展#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2050649, encodeId=19cc205064976, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 10 18:13:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254914, encodeId=b8361254914db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380779, encodeId=c9b31380e7943, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Apr 20 11:13:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188695, encodeId=515b18869547, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Wed Apr 19 07:19:47 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-04-19 tofsw

    学习了谢谢分享

    0

相关资讯

47个药物拼“钱途”！PD-1/PD-L1抗体太“火”了……

PD-1/PD-L1抗体是最惹人注目、最有“钱途”的抗癌免疫疗法之一。Opdivo 2016年全年销售额达37.74亿美元，Keytruda去年销售额达14.02亿美元。目前，国内外企业在这一领域的进展非常激烈。那么，在这种情况下，开发PD-1/PD-L1抗体需要考虑哪些问题呢？

JCO：阿司匹林对结直肠癌患者生存的影响与PD-L1表达有关

阻断PD-1免疫检查点信号通路可以改善肿瘤患者临床结局。有研究证据表明阿司匹林不仅能延长结直肠癌患者生存期，还能激活T细胞介导的抗肿瘤免疫，通过抑制前列腺素E2产生与免疫治疗协同发挥作用。

Science: 保持T细胞CD28/B7信号通路的激活对于针对PD-L1的靶向治疗具有重大意义

T细胞CD28/B7信号通路的激活是针对PD-L1的靶向治疗的重要组成部分

PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下

PD-1/PD-L1抗体是最惹人注目、最有“钱途”的抗癌免疫疗法之一。BMS的PD-1抗体Opdivo“手握”黑色素瘤、非小细胞肺癌、肾细胞癌、经典型霍奇金淋巴瘤、头颈癌以及膀胱癌六大适应症，2016年全年销售额达37.74亿美元。“老对手”默沙东的PD-1抗体Keytruda现在也拿下了4个适应症，去年销售额达14.02亿美元。罗氏公司拿下非小细胞肺癌以及膀胱癌两个适应症的PD-L1抗体Tece

陈列平：抗PD-1/PD-L1抗体治疗的三大原理

第一个原理，也是在概念上改变我们对肿瘤免疫认识的东西，叫免疫正常化，即Normalization。实际上，抗PD治疗（这里包括所有目标在于阻断这个通路的所有方法），在原理上并不是增强免疫反应，

JAMA Oncol：非小细胞肺癌的PD-L1检测，谁主沉浮？

PD-1/PD-L1单抗来了，面对肿瘤标本PD-L1的四种免疫组化检测方法：22c3、28-8、E1L3N和SP142提供的结果，如何判断是“真阳”还是“假阳”？如何用好这把“利器”？本研究发现， SP142只能发现其他3种方法检测出阳性病例的约50%。病理学家对肿瘤细胞的PD-L1表达的诊断评分上高度一致，但免疫细胞并不一致。